1. Home
  2. GNLN vs WINT Comparison

GNLN vs WINT Comparison

Compare GNLN & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNLN
  • WINT
  • Stock Information
  • Founded
  • GNLN 2005
  • WINT 1992
  • Country
  • GNLN United States
  • WINT United States
  • Employees
  • GNLN N/A
  • WINT N/A
  • Industry
  • GNLN Durable Goods
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GNLN Consumer Discretionary
  • WINT Health Care
  • Exchange
  • GNLN Nasdaq
  • WINT Nasdaq
  • Market Cap
  • GNLN 1.6M
  • WINT 1.5M
  • IPO Year
  • GNLN 2019
  • WINT 1995
  • Fundamental
  • Price
  • GNLN $0.27
  • WINT $1.20
  • Analyst Decision
  • GNLN
  • WINT Hold
  • Analyst Count
  • GNLN 0
  • WINT 1
  • Target Price
  • GNLN N/A
  • WINT $350.00
  • AVG Volume (30 Days)
  • GNLN 388.7K
  • WINT 7.7M
  • Earning Date
  • GNLN 03-21-2025
  • WINT 04-15-2025
  • Dividend Yield
  • GNLN N/A
  • WINT N/A
  • EPS Growth
  • GNLN N/A
  • WINT N/A
  • EPS
  • GNLN N/A
  • WINT N/A
  • Revenue
  • GNLN $13,275,000.00
  • WINT N/A
  • Revenue This Year
  • GNLN $1,541.21
  • WINT N/A
  • Revenue Next Year
  • GNLN N/A
  • WINT N/A
  • P/E Ratio
  • GNLN N/A
  • WINT N/A
  • Revenue Growth
  • GNLN N/A
  • WINT N/A
  • 52 Week Low
  • GNLN $0.26
  • WINT $1.10
  • 52 Week High
  • GNLN $21.80
  • WINT $737.50
  • Technical
  • Relative Strength Index (RSI)
  • GNLN 17.91
  • WINT 27.23
  • Support Level
  • GNLN $0.26
  • WINT $1.22
  • Resistance Level
  • GNLN $0.37
  • WINT $2.17
  • Average True Range (ATR)
  • GNLN 0.05
  • WINT 0.32
  • MACD
  • GNLN 0.01
  • WINT 0.20
  • Stochastic Oscillator
  • GNLN 0.76
  • WINT 3.54

About GNLN Greenlane Holdings Inc.

Greenlane Holdings Inc is a distributor of vaporization products and consumption accessories in the United States. It offers a selection of stock-keeping units including vaporizers and parts, cleaning products, grinders and storage containers, pipes, rolling papers and customized lines of premium specialty packaging. The company markets and sells its products in both the business to business and business to consumer sectors of the marketplace. Its geographical segment includes the United States; Canada and Europe. It derives a majority of revenue from the United States.

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Share on Social Networks: